These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1979953)

  • 1. Taxol treatment of experimental proliferative vitreoretinopathy.
    Daniels SA; Coonley KG; Yoshizumi MO
    Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):513-6. PubMed ID: 1979953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regular silicone and fluorosilicone oil in the prevention of retinal detachment caused by experimental proliferative vitreoretinopathy.
    Alghadyan A; Peyman GA; Fizer C; Tawakol M; Liu KR; Yue B; Peace JH
    Int Ophthalmol; 1988 Jan; 11(3):171-4. PubMed ID: 3417389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment.
    Chandler DB; Hida T; Sheta S; Proia AD; Machemer R
    Graefes Arch Clin Exp Ophthalmol; 1987; 225(4):259-65. PubMed ID: 3653718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.
    Khawly JA; Saloupis P; Hatchell DL; Machemer R
    Graefes Arch Clin Exp Ophthalmol; 1991; 229(5):464-7. PubMed ID: 1937080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol for the treatment of proliferative vitreoretinopathy.
    van Bockxmeer FM; Martin CE; Thompson DE; Constable IJ
    Invest Ophthalmol Vis Sci; 1985 Aug; 26(8):1140-7. PubMed ID: 2862129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
    Steinhorst UH; Chen EP; Machemer R; Hatchell DL
    Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring.
    Ward T; Hartzer M; Blumenkranz M; Lin LR
    Curr Eye Res; 1993 May; 12(5):397-401. PubMed ID: 8344064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.
    Chandler DB; Rozakis G; de Juan E; Machemer R
    Am J Ophthalmol; 1985 Jun; 99(6):686-90. PubMed ID: 2409802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy.
    Stern WH; Lewis GP; Erickson PA; Guerin CJ; Anderson DH; Fisher SK; O'Donnell JJ
    Am J Ophthalmol; 1983 Jul; 96(1):33-42. PubMed ID: 6869478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.
    Joondeph BC; Peyman GA; Khoobehi B; Yue BY
    Ophthalmic Surg; 1988 Apr; 19(4):252-6. PubMed ID: 3362494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of intraocular proliferations with intravitreal steroids.
    Machemer R; Sugita G; Tano Y
    Trans Am Ophthalmol Soc; 1979; 77():171-80. PubMed ID: 545825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 3,3'-iminodipropionitrile on experimental intravitreal proliferation in albino rabbits.
    Akiyama K
    Jpn J Ophthalmol; 1990; 34(4):401-8. PubMed ID: 2082060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.
    Chen EP; Steinhorst UH; Samsa GP; Saloupis PT; Hatchell DL
    Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2160-4. PubMed ID: 1607226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom.
    Yang CH; Huang TF; Liu KR; Chen MS; Hung PT
    Invest Ophthalmol Vis Sci; 1996 Apr; 37(5):843-54. PubMed ID: 8603869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
    Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
    Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits.
    Kuriyama S; Ohuchi T; Yoshimura N; Honda Y; Hiraoka M; Abe M
    Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):552-5. PubMed ID: 2265771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy.
    Yang CM; Olsen KR; Hernandez E; Cousins SW
    Graefes Arch Clin Exp Ophthalmol; 1992; 230(1):66-71. PubMed ID: 1547971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporary use of silicone oil in the treatment of proliferative vitreoretinopathy. An experimental study with a new animal model.
    Gonvers M; Thresher R
    Graefes Arch Clin Exp Ophthalmol; 1983; 221(1):46-53. PubMed ID: 6642220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological therapy for proliferative vitreoretinopathy.
    Radtke ND; Weinsieder AD; Ballou RJ
    Graefes Arch Clin Exp Ophthalmol; 1986; 224(3):230-3. PubMed ID: 3710177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations.
    Rahimy MH; Peyman GA; Fernandes ML; el-Sayed SH; Luo Q; Borhani H
    J Ocul Pharmacol; 1994; 10(3):561-70. PubMed ID: 7836865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.